Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benmelstobart - Apollomics/Chia Tai Tianqing Pharmaceutical Group

Next Previous
Drug Profile

Benmelstobart - Apollomics/Chia Tai Tianqing Pharmaceutical Group

Alternative Names: Anti-PD-L1 monoclonal antibody - Apollomics/Chia Tai Tianqing Pharmaceutical Group; APL 502; CBT-502; PD-L1 antibody - Apollomics/Chia Tai Tianqing Pharmaceutical Group​; TQ-B2450

Latest Information Update: 25 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apollomics; Crown Bioscience
  • Developer Apollomics; Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Small cell lung cancer
  • Preregistration Endometrial cancer
  • Phase III Biliary cancer; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Squamous cell cancer; Triple negative breast cancer
  • Phase II/III Adenocarcinoma; Gastric cancer
  • Phase II Diffuse large B cell lymphoma; Gynaecological cancer; Hepatitis B; Hodgkin's disease; Liver cancer; Nasopharyngeal cancer; Uterine cancer
  • Phase I/II Acral lentiginous melanoma; Cholangiocarcinoma
  • Preclinical Solid tumours

Most Recent Events

  • 30 May 2025 Efficacy and adverse event data from phase III trial in Non-small cell lung cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 30 May 2025 Efficacy and adverse events data from a phase II trial in Endometrial cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 30 May 2025 Adverse events and efficacy data from phase II trial in liver cancer presented at the61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top